The FDA has given the green light to expand the use of Moderna's vaccine for the treatment of RSV, the virus that causes ...

Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...

The Vaccines market is estimated to continue rising at a CAGR of 5.9%, reaching about USD 4,024.8 million by 2035 from USD 2,268.8 million in 2025. The vaccines market is a rapidly growing segment ...

The Advisory Committee on Immunization Practices (ACIP), made up of members recently hand-selected by Health and Human ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering ...

Moderna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations ...

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...